Therapeutic targeting of the IL-12/23 pathways: Generation and characterization of ustekinumab

Nature Biotechnology

Volumn 29, Issue 7, 2011, Pages 615-624

  Benson, Jacqueline M ^a   Sachs, Clifford W ^a   Treacy, George ^a   Zhou, Honghui ^a   Pendley, Charles E ^a   Brodmerkel, Carrie M ^a   Shankar, Gopi ^a   Mascelli, Mary A ^b  

^a CENTOCOR INC   (United States)

^b Biopharmaceutical Consultant   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EVALUATION; CLINICAL OBSERVATION; CLINICAL STUDY; CROHN'S DISEASE; CYTOKINES; MOLECULAR ENTITIES; MONOCLONAL ANTIBODIES (MAB); PSORIATIC ARTHRITIS; THERAPEUTIC AGENTS;

MONOCLONAL ANTIBODIES; PATHOLOGY;

DISEASES;

CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 23; PROTEIN P40; USTEKINUMAB;

ABSENCE OF SIDE EFFECTS; CLINICAL EVALUATION; CROHN DISEASE; DRUG TARGETING; HUMAN; IMMUNOGENICITY; MULTIPLE SCLEROSIS; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; TH17 CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; SIGNAL TRANSDUCTION;

EID: 79960209969     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1903     Document Type: Review

References (84)

1. Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A. & Coffman, R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136, 2348-2357 (1986). (Pubitemid 16136806)
2. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133-146 (2003). (Pubitemid 37328691)
3. Fiorentino, D.F., Bond, M.W. & Mosmann, T.R. Two types of mouse T helper cell IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170, 2081-2095 (1989).
4. Kobayashi, M. et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170, 827-845 (1989). (Pubitemid 19226667)
5. Presky, D.H. et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc. Natl. Acad. Sci. USA 93, 14002-14007 (1996).
6. Hong, K., Chu, A., Lúdvíksson, B.R., Berg, E.L. & Ehrhardt, R.O. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J. Immunol. 162, 7480-7491 (1999). (Pubitemid 29277728)
7. Leonard, J.P., Waldburger, K.E. & Goldman, S.J. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 181, 381-386 (1995).
8. Yawalkar, N., Karlen, S., Hunger, R., Brand, C.U. & Braathen, L.R. Expression of interleukin-12 is increased in psoriatic skin. J. Invest. Dermatol. 111, 1053-1057 (1998). (Pubitemid 29115174)
9. Davidson, N.J. et al. IL-12 but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10 deficient mice. J. Immunol. 161, 3143-3149 (1998). (Pubitemid 28425743)
10. Malfait, A.M. et al. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin. Exp. Immunol. 111, 377-383 (1998). (Pubitemid 28088321)
11. Monteleone, G. et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112, 1169-1178 (1997). (Pubitemid 27157528)
12. Berrebi, D. et al. Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease. Am. J. Pathol. 152, 667-672 (1998). (Pubitemid 28110712)
13. Windhagen, A. et al. Expression of costimulatory molecules B7-1 (Crohn's disease80), B7-2 (Crohn's disease86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 182, 1985-1996 (1995).
14. van Boxel-Dezaire, A.H. et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann. Neurol. 45, 695-703 (1999). (Pubitemid 29260746)
15. Nicoletti, F. et al. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J. Neuroimmunol. 70, 87-90 (1996). (Pubitemid 26323572)
16. Fassbender, K. et al. Increased release of interleukin-12p40 in MS: association with intracerebral inflammation. Neurology 51, 753-758 (1998). (Pubitemid 28449255)
17. Fishwild, D.M. et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 14, 845-851 (1996). (Pubitemid 26239182)
18. Luo, J. et al. Structural basis for dual recognition of IL-12 and IL-23 by ustekinumab. J. Mol. Biol. 402, 797-812 (2010).
19. Oppmann, B. et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13, 715-725 (2000).
20. Parham, C. et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168, 5699-5708 (2002). (Pubitemid 34556153)
21. Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F.J. & Gurney, A.L. Interleukin-23 promotes a distinct Crohn's disease4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910-1914 (2003). (Pubitemid 36801431)
22. Langrish, C.L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233-240 (2005). (Pubitemid 40189432)
23. Acosta-Rodriguez, E.V., Napolitani, G., Lanzavecchia, A. & Sallusto, F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8, 942-949 (2007). (Pubitemid 47300008)
24. Wilson, N.J. et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8, 950-957 (2007). (Pubitemid 47300009)
25. Trifari, S., Kaplan, C.D., Tran, E.H., Crellin, N.K. & Spits, H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 10, 864-871 (2009).
26. Staudt, V. et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 33, 192-202 (2010).
27. Murphy, K.M. & Stockinger, B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat. Immunol. 11, 674-680 (2010).
28. Zhou, L., Chong, M.M. & Littman, D.R. Plasticity of Crohn's disease4+ T cell lineage differentiation. Immunity 30, 646-655 (2009).
29. Curtis, M.M., Way, S.S. & Wilson, C.B. IL-23 promotes production of IL-17 by antigen-specific CD8 by CD T cells in the absence of IL-12 and type-I interferons. J. Immunol. 183, 381-387 (2009).
30. van de Wetering, D., de Paus, R.A. & van Dissel, J.T. & van de Vosse, E. IL-23 modulates Crohn's disease56+/Crohn's disease3-NK cell and Crohn's disease56+/Crohn's disease3+ NK-like T cell function differentially from IL-12. Int. Immunol. 21, 145-153 (2008).
31. Murphy, C.A. et al. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198, 1951-1957 (2003). (Pubitemid 38032126)
32. Gran, B. et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J. Immunol. 169, 7104-7110 (2002). (Pubitemid 36899299)
33. Cua, D.J. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744-748 (2003). (Pubitemid 36227625)
34. Torti, D.C. & Feldman, S.R. Interleukin-12, interleukin-23, and psoriasis: current prospects. J. Am. Acad. Dermatol. 57, 1059-1068; comment and author reply. 58, 1083 (2007).
35. Cargill, M. et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80, 273-290 (2007). (Pubitemid 46175676)
36. Capon, F. et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 122, 201-206 (2007). (Pubitemid 47241785)
37. Duerr, R.H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461-1463 (2006). (Pubitemid 44871953)
38. Di Meglio, P. et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector responses in humans. PLoS ONE 6, e17160 (2011).
39. Sachs, C. et al. Characterization of immune and asthmatic responses in cynomolgus macaques following antagonism of IL-12/23 activity with ustekinumab (CNTO 1275). The Toxicologist 102, Abstract 2141 (2008).
40. Gottlieb, A.B. & Dann, F. Comorbidities in patients with psoriasis. Am. J. Med. 122, 1150e1-1150e9 (2008).
41. Martin, P.L. et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res. 83, 1-13 (2010).
42. Naz, R.K. & Evans, L. Presence and modulation of interleukin-12 in seminal plasma of fertile and infertile men. J. Androl. 19, 302-307 (1998). (Pubitemid 28265106)
43. Buse, E., Habermann, G., Osterburg, I., Korte, R. & Weinbauer, G.F. Reproductive/developmental toxicity and immunogenicity assessment in the nonhuman primate model. Toxicology 221, 221-227 (2003). (Pubitemid 36173739)
44. Toichi, E. et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J. Immunol. 177, 4917-4926 (2006). (Pubitemid 44469828)
45. Kauffman, C.L. et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123, 1037-1044 (2004). (Pubitemid 39586823)
46. Fredriksson, T. & Pettersson, U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 157, 238-244 (1978). (Pubitemid 8387357)
47. Krueger, G.G. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356, 580-592 (2007). (Pubitemid 46220818)
48. Zhu, Y. et al. Pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation of CNTO 1275 in subjects with moderate to severe psoriasis vulgaris. J. Clin. Pharmacol. 47, 1203, Abstract 90 (2007).
49. Zhou, H. et al. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J. Clin. Pharmacol. 50, 257-267 (2010).
50. Wang, W., Wang, E.Q. & Balthasar, J.P. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84, 548-558 (2008).
51. Ghetie, V. & Ward, E.S. Transcytosis and catabolism of antibody. Immunol. Res. 25, 97-113 (2002). (Pubitemid 34264097)
52. Zhu, Y., Mendelsohn, A., Pendley, C., Davis, H.M. & Zhou, H. Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis. Int. J. Clin. Pharmacol. Ther. 48, 830-846 (2010).
53. Zhu, Y. et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J. Clin. Pharmacol. 49, 162-175 (2009).
54. Sandborn, W.J. et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135, 1130-1141 (2008).
55. Gottlieb, A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373, 633-640 (2009); errata in 373, 1340 (2009) and 376, 1542 (2010).
56. Segal, B.M. et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7, 796-804 (2008).
57. Zhou, H. Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures? J. Clin. Pharmacol. 46, 1268-1289 (2006). (Pubitemid 44564356)
58. Zhou, H. & Davis, H.M. Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Drug Discov. Today 14, 891-898 (2009).
59. Reddy, M. et al. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J. Dermatol. 37, 413-425 (2010).
60. Nestle, F.O. et al. Psoriasis. N. Engl. J. Med. 361, 496-509 (2009).
61. Looney, R.J. et al. Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clin. Immunol. 123, 235-243 (2007). (Pubitemid 46824125)
62. Brodmerkel, C. et al. Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions. J. Drugs Dermatol. 9, 677-683 (2010).
63. Leonardi, C.L. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665-1674 (2008); erratum in: 1838 (2008). (Pubitemid 351671883)
64. Griffiths, C.E. et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362, 118-128 (2010).
65. Papp, K.A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675-1684 (2008). (Pubitemid 351671884)
66. Schellekens, H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 24, 1720-1740 (2002); discussion 1719 (2002). (Pubitemid 35440946)
67. Lowes, M.A. et al. Pathogenesis and therapy of psoriasis. Nature 445, 866-873 (2007).
68. Shigehara, K. et al. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J. Immunol. 166, 642-649 (2001). (Pubitemid 32038488)
69. Judson, M. et al. Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of IL-12, IL-23, and the Th17 pathways. J. Amer. Acad. Derm. (in the press).
70. Bowman, E.P., Chackerian, A.A. & Cua, D.J. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr. Opin. Infect. Dis. 19, 245-252 (2006). (Pubitemid 43740362)
71. Torti, D.C. & Feldman, S.R. Interleukin-12, interleukin-23, and psoriasis: current prospects. J. Am. Acad. Dermatol. 57, 1059-1068 (2007).
72. Airoldi, I. et al. Lack of IL12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood 106, 3846-3853 (2005). (Pubitemid 41739022)
73. Street, S.E., Trapani, J.A., MacGregor, D. & Smyth, M.J. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J. Exp. Med. 196, 129-134 (2002). (Pubitemid 34747318)
74. Leonard, J.P. et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90, 2541-2548 (1997). (Pubitemid 27413462)
75. Portielje, J.E. et al. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin. Cancer Res. 5, 3983-3989 (1999). (Pubitemid 30013774)
76. Steinman, L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T-cell-mediated tissue damage. Nat. Med. 13, 139-145 (2007).
77. Laurence, A. & O'Shea, J.J. T(H)-17 differentiation: of mice and men. Nat. Immunol. 8, 903-905 (2007).
78. Novelli, F. & Casanova, J.L. The role of IL-12, IL-23 and IFN-gamma in immunity to viruses. Cytokine Growth Factor Rev. 15, 367-377 (2004). (Pubitemid 39140700)
79. Fieschi, C. & Casanova, J.L. The role of interleukin-12 in human infectious diseases: only a faint signature. Eur. J. Immunol. 33, 1461-1464 (2003). (Pubitemid 36790405)
80. Filipe-Santos, O. et al. Inborn errors of IL-12/23-and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin. Immunol. 18, 347-361 (2006). (Pubitemid 44540199)
81. Cárdenes, M. et al. Oesophageal squamous cell carcinoma in a young adult with Il-12Rβ1 deficiency. J. Med. Genet. 47, 635-637 (2010).
82. Gottlieb, A.B. et al. A phase I double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr. Med. Res. Opin. 23, 1081-1092 (2007). (Pubitemid 46799592)
83. Kasper, L.H. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr. Med. Res. Opin. 22, 1671-1678 (2006). (Pubitemid 44449223)
84. Dillon, S.R. New mechanisms and expanded indications for biologic therapies: a perspective on immunology research and development. Drug Disc. World Fall, 87-93 (2010).